The Company announces that the Board of Directors has approved the granting of 2,948,056 stock options to directors and a consultant of the Company. Of the options, 2,798,056 were granted to directors of the Company. The Options are exercisable (''vested'') at a price of $0.18 on grant date, for a period of 10 years following the grant date. The Board of Directors has also approved the granting of 385,950 stock options to employees of the Company as part of their performance bonus and as retainer. In additi ...

Core Insights - Devonian Health Group Inc. has published a peer-reviewed article in Biomedicines highlighting the anti-inflammatory properties of its lead pharmaceutical candidate, Thykamine™ [1][2] - The study demonstrates that Thykamine™ exhibits greater potency in inhibiting inflammatory markers compared to six widely prescribed anti-inflammatory drugs [3][4] - Thykamine™ is positioned as a promising candidate for treating chronic inflammatory conditions due to its favorable safety profile and multi-target efficacy [4][6] Company Overview - Devonian Health Group Inc. specializes in developing prescription drugs for fibroinflammatory diseases and has a focus on unmet medical needs in autoimmune inflammatory conditions [10] - The company’s first pharmaceutical product, Thykamine™, is derived from its SUPREX™ platform and has shown efficacy in treating conditions like ulcerative colitis and atopic dermatitis [8][10] - Devonian is publicly traded on the TSX Venture Exchange and OTCQB Venture Market, and it operates a state-of-the-art extraction facility in Québec, Canada [12]

Core Viewpoint - Devonian Health Group Inc. reported its financial results for the fourth quarter and fiscal year ended July 31, 2025, highlighting a debt-free status and a strategic focus on advancing its Thykamine™ programs in the fibro-inflammatory space [2][5]. Financial Highlights - Fourth quarter distribution revenues were $1.3 million, representing an 87% decrease year over year, primarily due to the expiration of the distribution agreement for Dexlansoprazole [5][6]. - Annual distribution revenues totaled $23.6 million, marking a 22% increase year over year, with Dexlansoprazole accounting for 93% of these revenues [5][6]. - The company reported a fourth quarter net loss of $0.4 million, or $0.003 per share, compared to a net income of $0.75 million, or $0.003 earnings per share in the same quarter last year [5][6]. - For the fiscal year, the net loss was $6 million, or $0.041 per share, compared to a net loss of $1.83 million, or $0.012 per share in the previous year, largely due to a one-time goodwill impairment loss of $4.6 million [5][6]. - As of July 31, 2025, the company had $7 million in cash and was debt-free after repaying its long-term debt of $2.2 million during the fiscal year [5][6]. Business Highlights - Devonian completed preclinical studies to explore new applications of Thykamine™ for additional inflammatory diseases, including MASH and fibrosis [6]. - The company is focusing on a phase 2/3 study of Thykamine™ for pediatric mild-to-moderate atopic dermatitis [6]. - Devonian secured additional patent protection related to the mechanisms of action and other therapeutic applications of Thykamine™ [6]. - Pierre Labbé was appointed as a new board member, bringing extensive financial experience to the board [8][9]. About Thykamine™ - Thykamine™, developed from Devonian's SUPREX™ platform, is aimed at treating health conditions related to inflammation and oxidative stress, including ulcerative colitis and atopic dermatitis [13][14]. - The product has demonstrated anti-inflammatory, anti-oxidative, and immunomodulatory properties in various studies [13]. Company Overview - Devonian Health Group Inc. is a clinical stage pharmaceutical company focused on developing drugs for autoimmune inflammatory conditions, leveraging over 15 years of research [14][15]. - The company operates a state-of-the-art extraction facility in Québec and is publicly traded on the TSX Venture Exchange and OTCQB Venture Market [16].